scholarly journals Early embryonic exposure of freshwater gastropods to pharmaceutical 5-alpha-reductase inhibitors results in a surprising open-coiled “banana-shaped” shell

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Alice Baynes ◽  
Gemma Montagut Pino ◽  
Giang Huong Duong ◽  
Anne E. Lockyer ◽  
Carmel McDougall ◽  
...  

Abstract In vertebrates, the steroidogenesis enzyme 5α-reductase converts testosterone to the more potent androgen 5α-dihydrotestosterone. Homologues of 5α-reductase genes have been identified in molluscs. However, recent findings suggest that vertebrate-type steroid androgens are not utilised in molluscan reproductive development. Genomic searches have revealed that molluscs do not possess many of the steroidogenic enzymes required to make testosterone, nor a nuclear androgen receptor. Consequently, the role of 5α-reductase in molluscs presents a mystery. Here, developmental exposures of Biomphalaria glabrata to selective pharmaceutical 5α-reductase inhibitors elicited a strong, highly reproducible phenotypic response characterised by the development of elongated “banana-shaped” shell morphology. In comparison to untreated snails, the shells are open-coiled and the whorls are unattached. Dutasteride (5α-reductase inhibitor) is approximately 10-times more potent at provoking the banana-shaped shell phenotype than finasteride, paralleling the pharmaceuticals’ efficacy in humans. Other enzyme inhibitors with different modes of action were tested to investigate the specificity of the phenotype. However, only the pharmaceutical 5α-reductase inhibitors provoked the response. Dutasteride elicited the same phenotype in a second gastropod, Physella acuta. In the absence of evidence for de novo androgen steroidogenesis in molluscs, these findings suggest that novel substrates for 5α-reductase exist in gastropods, lending support to the contention that molluscan endocrinology differs from the well-characterised vertebrate endocrine system.

2006 ◽  
Vol 1 (4) ◽  
pp. 425-431 ◽  
Author(s):  
Steven J Hudak ◽  
Javier Hernandez ◽  
Ian M Thompson

2012 ◽  
pp. 57-62
Author(s):  
Norma Marigliano ◽  
Domenico Galasso

Benign prostatic hyperplasia (BPH) is a disease that affects over 50% of males aged 50 years or older. In men aged >80 years, the incidence is 90%. BPH occurs in 9-25% of males aged 40 to 79 years. Fifty percent of patients with BPH are symptomatic. The symptoms include reduced urinary flow, nocturia, defective bladder emptying, urinary hesitancy, and dysuria. Disease progression can be associated with acute urinary retention (AUR). Prostatic obstruction includes mechanical and dynamic components, the latter mediated by alpha-muscarinic receptors. Treatment with alpha-1-blockers (alfuzosin, doxazosin, tamsulosin, and terazosin) leads to rapid amelioration of symptoms and urinary flow, usually within one or two weeks. The 5-alpha reductase inhibitors (5-ARIs) are “disease-modifying drugs.” They control the growth of the prostate by blocking the conversion of testosterone into dihydrotestosterone (DHT). Finasteride is a 5–ARI that is selective for type 2 receptors. Dutasteride is a powerful inhibitor of both 5- alpha reductase isoforms (type 1 and 2) and produces more complete suppression of DHT synthesis than finasteride. Dutasteride also has a much longer half-life than finasteride (five weeks versus five to six hours). The authors review the results of clinical trials involving finasteride and dutasteride, with and without alpha-1-blockers, highlighting the important role of dutasteride in improving acute urinary retention and eliminating the need for surgical therapy.


2013 ◽  
Vol 3 (3-S2) ◽  
pp. 109 ◽  
Author(s):  
Larry Goldenberg ◽  
Alan So ◽  
Neil Fleshner ◽  
Ricardo Rendon ◽  
Darrel Drachenberg ◽  
...  

Normal growth and function of the prostate are contingent on the reductionof testosterone to dihydrotestosterone (DHT) by 5-alpha reductase(5-AR) enzymes types 1 and 2. It has been theorized that an overabundanceof DHT may be implicated in the pathogenesis of both benign prostatic hyperplasia(BPH) and prostate cancer. Inhibitors of 5-AR such as dutasteride andfinasteride may therefore have an important role in the prevention and treatmentof BPH and prostate cancer. Dutasteride provides greater suppression ofDHT than finasteride, thereby underlying the hypothesis that inhibition of bothtype 1 and type 2 would provide correspondingly greater protection than inhibitionof type 2 alone. We review the potential significance of the 5-ARinhibitors in reducing the risk of prostate cancer according to the basic biologyof prostate disease


2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Antonio Luigi Pastore* ◽  
Cosimo De Nunzio ◽  
Matteo Balzarro ◽  
Yazan Al salhi ◽  
Andrea Fuschi ◽  
...  

2019 ◽  
Vol 18 (9) ◽  
pp. e3200-e3201
Author(s):  
A. Pastore ◽  
C. De Nunzio ◽  
M. Balzarro ◽  
Y. Al Salhi ◽  
A. Fuschi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document